Clinical Trials · NCT00175396
Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- University of British Columbia
- Enrollment
- 400
- Start date
- May 2004
- Locations
- 1 site, Canada
- Primary endpoint
- The primary end point of this trial is 5 year actuarial freedom from biochemical recurrence (5 year bNED) using the Houston definition of biochemical failure.